Predictors of response to anti-TNF therapy in ankylosing spondylitis: Results from the British Society for Rheumatology Biologics Register

Rheumatology

Volumn 49, Issue 3, 2009, Pages 563-570

  Lord, Paul A C ^a   Farragher, Tracey M ^a   Lunt, Mark ^a   Watson, Kath D ^a   Symmons, Deborah P M ^a   Hyrich, Kimme L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Adalimumab; Ankylosing spondylitis; Anti TNF; Disability; Etanercept; Infliximab; Treatment effectiveness; Treatment response

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; COHORT ANALYSIS; DISEASE DURATION; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGISTER; SCORING SYSTEM; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950525609     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep422     Document Type: Article

References (24)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90.
2. Francois RJ, Neure L, Sieper J et al. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 2006;65:713-20.
3. Davis JC Jr, Van der HD, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
4. Van der HD, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
5. Van der HD, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results Predictors of response to anti-TNF therapy in AS of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
6. Keat A, Barkham N, Bhalla A et al. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology 2005;44:939-47.
7. van der LS, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
8. Garrett S, Jenkinson T, Kennedy LG et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
9. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44:157-63.
10. Nikas SN, Alamanos Y, Voulgari PV et al. Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis 2005;64:940-2.
11. Stone MA, Payne U, Pacheco-Tena C et al. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004;63:84-7.
12. Rudwaleit M, Listing J, Brandt J et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
13. Konttinen L, Tuompo R, Uusitalo T et al. Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience. Clin Rheumatol 2007;26:1693-700.
14. Gadsby K, Deighton C. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis. Rheumatology 2007;46:439-41.
15. Heiberg MS, Koldingsnes W, Mikkelsen K et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234-40.
16. Rudwaleit M, Claudepierre P, Wordsworth P et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009;36:801-8.
17. Silman A, Symmons D, Scott DG et al. British Society for Rheumatology Biologics Register. Ann Rheum Dis 2003;62(Suppl. 2):ii28-9.
18. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
19. Davis JC Jr, van der Heijde DM, Dougados M et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 2005;32:1751-4.
20. Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999;26:966-70.
21. Hyrich KL, Watson KD, Silman AJ et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558-65.
22. Brockbank JE, Schimmer J, Schentag C et al. Spinal disease assessment in psoriatic arthritis (PsA) [Abstract]. J Rheumatol 2001;28:62.
23. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
24. Hyrich KL, Symmons DP, Watson KD et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:1786-94.